
Shikari® (S-ATR) Anti-Rituximab ELISA
RIT-QLS-RM
Enzyme immunoassay for the qualitative determination of specific antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma.
This kit has been especially developed for the qualitative determination of specific antibodies to Rituximab in serum and plasma samples.
The Matriks Biotek Antibody to Rituximab (Rituxan®, Mabthera®) Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to rituximab (Rituxan®, Mabthera®) in serum and plasma.Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
Required Volume (µl) | 20 |
Total Time (min) | 140 |
Sample | Serum, plasma |
Sample Number | 96 |
Detection Limit (ng/mL) | + / - |
Spike Recovery (%) | - |
Shelf Life (year) | 1 |
Assay type | Qualitative |
Species Reactivity | Human |
Storage conditions | Store at +4°C. Please refer to protocols. |
Shipping conditions | At room temperature |
# | File | Action |
---|---|---|
Instructions For Use | Download | |
Safety Data Sheet (SDS) | Download |
Publications with this drug
# | File | Action |
---|---|---|
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects." Nephrology Dialysis Transplantation 38.4 (2023): 939-949. | Visit Link | |
Chen, Yewei, et al. "Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome." Frontiers in Pharmacology 12 (2021): 725665. | Visit Link | |
Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science 15.3 (2022): 680-690. | Visit Link | |
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica 42.4 (2021): 641-647. | Visit Link | |
Bai, Yunfei, et al. "Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody." Frontiers in Immunology 14 (2023): 1121705. | Visit Link | |
Chen, Yewei, et al. "Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study." Frontiers in Pharmacology 14 | Visit Link | |
Abdullah, Iqbal Muaafi, et al. "The Diagnostic Value of Anti-rituximab Ab in Iraqi Patient with Chronic Lymphocytic Leukemia." International journal of health sciences 6.S6: 3005-3013. | Download |